Zosano Pharma EBIT

Zosano Pharma (ZSAN) currently reports a EBIT of $-55M as of March 2022. That compares with $-32M in the prior-year period — down 70.8% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Zosano Pharma's EBIT history and peer comparisons.

Zosano Pharma's EBIT decreased from $-32M to $-55M — a 70.8% year-over-year decrease (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Zosano Pharma's EBIT of $-55M is lower than the Healthcare sector average of $23B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Zosano Pharma reported $-55M in EBIT as of March 2022. That compares with $-32M in the prior-year period — down 70.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-55M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Zosano Pharma, and consider following ZSAN for alerts when major investors trade the stock.